Search PubMed⌕ Search

Biomedical subjects

M Schattenkirchner

Publications and source records attributed to M Schattenkirchner.

At least 127 records · Page 7Linked to original sources
PubMedDate not supplied

[The medical computer as a diagnostic aid in joint pain--attitude of patients and results].

409 unselected outpatients were asked standardized expert system questions on the medical history of joint complaints. An average number of 30.4 +/- 6.6 out of 60 questions with 346 different answers were asked in a mean time of 20.1 +/- 6.6 min. This time, required for the questions to be displayed on the computer screen and input assistance from a staff-member, proved to be comparable to the time required for a medical history to be taken on the same patients by a physician. In 75% of the cases the computer was able to predict the correct diagnosis on behalf of information of the medical history only. Using only medical history as a source of information, computer and physician had the same rate of wrong diagnoses. Before and after the standardized medical history on the computer screen all patients were asked about their opinion of the computer as a diagnostic aid. Male and younger patients more often appreciated computerized diagnosing. Just a few patients felt that their relation to the physician was disturbed by the computer or were inconvenienced themselves. Most patients stated they did not believe that physicians could ever be replaced by computers. Only a few of them had resignations about storage and statistical utilization of personal data.

Adult↗
PubMedDate not supplied

[The treatment of ankylosing spondylitis with auranofin (Ridaura)].

Auranofin has no influence on axial skeleton manifestation of ankylosing spondylitis, neither on clinical complaints, nor on function and inflammatory parameters. Peripheral arthritis is possibly influenced positively, but this cannot be stated definitely because of the low number of cases in this study. This question must be analyzed in larger collectives, as alternatives to conventional therapy are needed for the treatment of peripheral joint involvement of ankylosing spondylitis.

Auranofin↗
PubMedDate not supplied

[Hemorheologic changes in chronic polyarthritis].

The haemorheological status of plasma-(P eta) and blood-viscosity (B eta), erythrocyte aggregation (EA) and erythrocyte filterability (EF), blood sedimentation rate (BSG), haematocrit (HCT), plasma fibrinogen and alpha-2-macroglobulin was investigated on 46 patients suffering from chronic polyarthritis (c.P.). The results were compared with those from a control group of 20 healthy subjects with a similar distribution of age and sex. All the haemorheological data from the c.P. patients showed a significantly decreased blood fluidity (p less than or equal to 0.001 or p less than or equal to 0.01). These differences were highly significant for the female patients (n = 29), but for the men (n = 17) only at slight shift was seen. The comparison of clinically acute and non-acute disease in the patients showed a significant worsening of P eta, B eta and EF during the acute state, while the EA remained unaffected. The limited blood fluidity is seen as a result of the basic illness. At present, the pathophysiological meaning of these findings is still hypothetical: further investigations are required.

Arthritis, Rheumatoid↗
PubMedDate not supplied

[Coexistence of polymyalgia rheumatica/temporal arteritis and chronic polyarthritis].

Prompted by one of our own case studies, which we report here, we reviewed the literature for coincidence of rheumatoid arteritis (RA) with polymyalgia rheumatica (PMR) and temporal arteritis (TA), respectively. The indicative feature of this uncommon condition was found in 13 cases, whereas in 70 other cases reported, the diagnosis of combined RA and PMR/TA was probable. Diagnostic criteria for determining combined RA and PMR/TA will be discussed, as well as the clinical important feature of senile RA.

Arthritis, Rheumatoid↗
PubMedDate not supplied

[Joint involvement in polymyalgia rheumatica/temporal arteritis].

The coincidence of arthritis with polymyalgia rheumatica (PMR) or temporal arteritis (TA) is not well established. After reviewing the literature we found that 22% of patients suffering from PMR/TA present with additional signs of inflammatory joint involvement. Joints predominantly affected are the sternal junctions, knee and shoulder joints, and the wrists, involvement of the latter frequently resulting in carpal tunnel syndrome. With the exception of sternal junctions, bony erosions are rarely seen. In most cases, synovitis is mild, pauciarticular, asymmetrical, transient and not destructive. Little evidence for inflammatory involvement of spine or sacroiliac joints was found, thus, back pain in these patients should be considered as caused by osteoporosis of the spinal column, mostly due to prolonged corticosteroid treatment.

Arthritis↗
PubMedDate not supplied

[The pincer-nail syndrome--a rare differential diagnosis of finger end joint-/nail involvement].

A 55-year-old patient who clinically presented with a Heberden arthrosis and gryphosis of the second and fourth finger nails of the left hand was admitted to our outpatient department under the tentative diagnosis of psoriatic arthritis. Nature of nail damage and combination of clinical findings suggested the diagnosis of a pincer-nail syndrome. The pathogenesis of this rare disease is not yet clear. Its complete clinical picture includes gryphosis of finger and toe nails in combination with acroosteolytic shortening of the end-phalanx and destructive arthrosis of the terminal joints of toes and fingers. Since deformation of the nail, which sometimes includes inflammation of the nail bed, may cause marked pain, surgical intervention with excision of the nail and, if necessary, revision of the nail bed has to be performed in most cases.

Arthritis↗
PubMedDate not supplied

[Sulfasalazine (Azulfidine RA) versus aurothioglucose in therapy of chronic polyarthritis--status report of an open, comparative, multicenter long-term study].

In a current German multicenter comparative study a minimum of 2 X 58 patients with active rheumatoid arthritis (RA) will be treated 36 weeks with sulfasalazine or aurothioglucose. The total time of observation will be 2 years. Up to September 1986 191 patients were recruited in the study, 81 patients divided into two treatment groups were treated for 36 weeks. A preliminary evaluation shows a significant reduction of the parameters of disease activity in both groups. In the sulfasalazine group favourable changes occur earlier than in the gold group. In comparison with gold sulfasalazine shows up to advantage concerning benefit/risk-ratio measured by the rate of side effects causing cessation of therapy and the rate of positive therapeutic response. On the basis of the preliminary data a comparison of grade and duration of ameliorations and of long-term tolerance of the two treatment regimens is not possible.

Adolescent↗
PubMedDate not supplied

[Pasteurella multocida as a cause of septic arthritis in the elderly].

Pasteurella multocida as cause of septic arthritis was only reported in patients with underlying joint damage or altered systemic host defense. We report a case of septic arthritis of the shoulder in a 92-year-old, previously healthy woman. It is concluded that Pasteurella multocida can cause septic arthritis in aged persons without precedent joint damage.

Aged↗
PubMedDate not supplied

[Lymphocytapheresis in the treatment of chronic polyarthritis. Effect on clinical and laboratory chemical parameters and lymphocyte function].

Ten patients with rheumatoid arthritis (RA) were treated by lymphocytapheresis. Only patients with severe disease (Steinbrocker classification III/IV, at least two disease-modifying drugs previously unsuccessful, present treatment insufficient) were selected, concomitant treatment was standardized (NSAID and/or low-dose steroids in a fixed dose, administered constantly for 6 weeks). Using an IBM cell-separator, apheresis was administered three times per week for 2 weeks with continuation only in the case of improvement. Lymphocyte elimination rate was 10(9)-10(10) per apheresis in all cases. Only three patients showed significant clinical improvement (evaluated by the Ritchie Index, grip strength and morning stiffness), little (5 patients) or nor (2 patients) change was registered in the other cases. No side effects occurred during treatment. Standard laboratory parameters (including rheumatoid factor, circulating IC) showed no correlations with the course or success of treatment. Interestingly, all therapy responders showed a markedly depressed lymphocyte proliferative capability (LPC, tested with tetanus toxoid/streptodornase as antigens) compared to the non-responders before apheresis, with complete reversal to normal LPC during treatment. Lymphocytapheresis might be a promising additional treatment in a minority of RA patients characterized by a certain form of lymphocyte dysfunction. Markers to preselect such a subgroup are still to be found.

Arthritis, Rheumatoid↗
PubMedDate not supplied

[Long-term treatment of chronic polyarthritis using benorylate].

The antiphlogistic and analgesic effect and the compatibility of benorylate, a acetamidophenyl-acetoxy-benzoate, was tested in 33 patients with rheumatoid arthritis in an open study over a period of 6 months. Benorylate is particularly qualified for treatment of a beginning rheumatoid arthritis and for diseases with a low inflammatory activity. For patients with high inflammatory activity treatment with this substance alone is not sufficient. Side effects are mainly subjective troubles. Severe side effects were not observed. Besides the usual laboratory investigations a regular control of the blood count is advisable during long term treatment. Like with other antirheumatic drugs occasional investigations of the stool for occult blood are recommended.

Arthritis, Rheumatoid↗
PubMedDate not supplied

Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study.

Auranofin (AF), a new gold compound, has been suggested as an alternative to parenteral gold in the treatment of rheumatoid arthritis (RA). This hypothesis has been tested within a double-blind comparative study and to date 103 patients have been enrolled. Forty-one RA patients have been treated for longer than 6 months. The patients were randomly allocated to treatment with either AF or sodium aurothiomalate (GSTM) and serial comparison of changes within the articular index, grip strength, pain, morning stiffness, and global assessment during treatment were measured. Improvement was noted within both treatment groups. Diarrhea as a side effect was most commonly seen during treatment with AF while rash often combined with pruritus was most commonly reported with GSTM; withdrawal from treatment as the result of this was nevertheless uncommon.

Arthritis, Rheumatoid↗